Intravitreous anti-VEGF for diabetic retinopathy: Hopes and fears for a new therapeutic strategy

Diabetologia

Volumn 51, Issue 9, 2008, Pages 1574-1580

  Simo R ^a   Hernandez C ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bevacizumab; Diabetic retinopathy; Pegaptanib; Ranibizumab; VEGF inhibitors; VEGF isoforms

Indexed keywords

BEVACIZUMAB; ISOPROTEIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; Y 0317;

ANGIOGENESIS; BLEEDING; BLOOD PRESSURE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETIC RETINOPATHY; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOPHTHALMITIS; HUMAN; HYPERTENSION; INTRAVITREAL DRUG ADMINISTRATION; KIDNEY CANCER; LENS DISEASE; MEDICAL DECISION MAKING; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; RETINA DETACHMENT; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; STROKE; SUBRETINAL NEOVASCULARIZATION; TRAUMATIC INJURY OF THE LENS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION; PROTEINURIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49349103253     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-008-0989-9     Document Type: Review

References (65)

1. N Congdom DS Friedman T Lietman 2003 Important causes of visual impairment in the world today JAMA 290 2057 2060
2. L Tong SA Vernon W Kiel V Sung GM Orr 2001 Association of macular involvement with proliferative retinopathy in type 2 diabetes Diabet Med 18 388 394
3. R Klein BE Klein SE Moss MD Davis DL Demets 1984 The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years Arch Ophthalmol 102 527 532
4. RB Cladwell M Bartoli MA Behzadian 2003 Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives Diabetes Metab Res Rev 19 442 455
5. C Hernández R Simó 2007 Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice Expert Opin Invest Drugs 16 1209 26
6. RF Spaide YL Fisher 2006 Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina 26 275 278
7. Y Oshima H Sakaguchi F Gomi Y Tano 2006 Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy Am J Ophthalmol 142 155 158
8. E Chen CH Park 2006 Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy Retina 26 699 700
9. RL Avery J Pearlman DJ Pieramici 2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 1695.e1 15
10. R Jorge RA Costa D Calucci LP Cintra IU Scott 2006 Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina 26 1006 1013
11. Arevalo JF, Wu L, Sanchez JG et al (2008) Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye DOI 10.1038/sj.eye.6702980
12. Ishikawa K, Honda S, Tsukahara Y, Negi A (2008) Preferable use of intravitreal bevacizumab as a pre-treatment of vitrectomy for severe proliferative diabetic retinopathy. Eye DOI 10.1038/sj.eye.6702983
13. ET Cunningham Jr AP Adamis M Altaweel 2005 A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 1747 1757
14. DW Chun JS Heier TM Topping JS Duker JM Bankert 2006 A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema Ophthalmology 113 1706 1712
15. QD Nguyen S Tatlipinar SM Shah 2006 Vascular endothelial growth factor is a critical stimulus for diabetic macular edema Am J Ophthalmol 142 961 969
16. C Haritoglou D Krook A Neubauer 2006 Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 999 1005
17. JF Arevalo J Fromow-Guerra H Quiroz-Mercado 2007 Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology 114 743 50
18. Diabetic Retinopathy Clinical Research Network 2007 A Phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema Ophthalmology 114 1860 1867
19. Ahmadieh H, Ramezani A, Shoeibi N et al (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246:483-489
20. A Kumar S Sinha 2007 Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population Indian J Ophthalmol 55 451 455
21. ES Gragoudas AP Adamis ET Cunningham M Feinsod DR Guyer 2004 Pegaptamib for neovascular age-related macular degeneration N Engl J Med 351 2805 2816
22. PJ Rosenfeld DM Brown JS Heier 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431
23. DM Brown PK Kaiser M Michels 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432 1444
24. JS Heier DS Boyer TA Ciulla 2006 Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study Arch Ophthalmol 124 1532 1542
25. N Ferrara 2001 Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol 280 C1358 C1366
26. H Takahashi M Shibuya 2005 The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions Clin Sci (Lond) 109 227 241
27. 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization J Exp Med 198 483 489
28. V Eremina M Sood J Haigh 2003 Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 11 707 716
29. NN Nissen PJ Polverini AE Koch MV Volin RL Gamelli LA DiPietro 1998 Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing Am J Pathol 152 1445 1452
30. T Asahara T Takahashi H Masuda 1999 VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells EMBO J 18 3964 3972
31. T Yasukawa Y Ogura Y Tabata H Kimura P Wiedemann Y Honda 2004 Drug delivery systems for vitreoretinal diseases Prog Retin Eye Res 23 253 281
32. RR White BA Sullenger CP Rusconi 2000 Developing aptamers into therapeutics J Clin Invest 106 929 934
33. Eyetech Study Group 2002 Preclinical and Phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration Retina 22 143 152
34. 164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2 Invest Ophthalmol Vis Sci 45 368 374
35. KJ Kim B Li K Houck 1992 The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies Growth Factors 7 53 64
36. Y Chen C Wiesmann G Fuh 1999 Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen J. Mol Biol 293 865 881
37. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pathol 27 536 544
38. MG Krzystolilk MA Afshari AP Adamis 2002 Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment Arch Ophthalmol 120 338 346
39. PK Kaiser 2006 Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases Am J Ophthalmol 142 660 668
40. PJ Rosenfeld 2006 Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 142 141 143
41. A Luttun P Carmeliet 2003 Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 11 600 602
42. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 186 193
43. T Kamba DM McDonald 2007 Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 2007 96 1788 1795
44. E Chou I Suzuma JW Kerrie 2002 Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue Circulation 105 373 379
45. JA Beckman MA Creager P Libby 2002 Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2570 2581
46. P Hogan T Dall P Nikolov 2003 Economic costs of diabetes in the U.S. in 2002 Diabetes Care 26 917 932
47. Centres for Disease control and Prevention (CDC) 2005 Incidence of end-stage renal disease among persons with diabetes-United States, 1990-2002 MMWR Morb Mortal Wkly Rep 54 1097 1100
48. RS Most P Sinnock 1983 The epidemiology of lower extremity amputations in diabetic individuals Diabetes Care 6 87 91
49. V Falanga 2005 Wound healing and its impairment in the diabetic foot Lancet 366 1736 1743
50. L Dalla Paola E Faglia 2006 Treatment for diabetic foot ulcer: an overview strategies Curr Diabetes Rev 2 431 447
51. HG Blaauwgeers GM Holtkamp H Rutten 1999 Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation Am J Pathol 155 421 428
52. AG Marneros J Fan Y Yokoyama 2005 Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function Am J Pathol 167 1451 1459
53. K Nishijima N Yin-Shan L Zhong 2007 Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 53 67
54. SJ Bakri JD Cameron CA McCannel JS Pulido RJ Marler 2006 Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model Am J Ophthalmol 142 162 164
55. A Iriyama YN Chen Y Tamaki Y Yanagi 2007 Effect of the anti-VEGF antibody on the retinal ganglion cell of rat Br J Ophthalmol 91 1230 1233
56. S Luthra R Narayanan LE Marques 2006 Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells Retina 26 512 518
57. MS Spitzer B Wallenfels-Thilo A Sierra 2006 Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells Br J Ophthalmol 90 1316 1321
58. MS Spitzer E Yoeruek A Sierra 2007 Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells Graefes Arch Clin Exp Ophthalmol 245 1837 42
59. UU Inan B Avci T Kusbeci B Kaderli R Avci SG Temel 2007 Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes Invest Ophthalmol Vis Sci 48 1773 1781
60. S Peters P Heiduschka S Julien 2007 Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab Am J Ophthalmol 143 995 1002
61. PA D'Amore 2007 Vascular endothelial cell growth factor-a: not just for endothelial cells anymore Am J Pathol 171 14 18
62. F Kabbinavar H Hurwitz L Fehrenbacher 2000 Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/lecovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer N Engl J Med 343 905 914
63. JC Yang L Haworth RM Sherry 2003 A randomised trial of bevacizumab, an anti-vascular endothelial cell growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434
64. AA Moshfeghi PJ Rosenfeld CA Puliafito 2006 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study Ophthalmology 113 2002 2011
65. AP Adamis M Altaweel NM Bressler 2007 Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals Ophthalmology 114 615 616